SM
ICPT

SG3 Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

SG3 Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,267
Closed -$139K – 1355
2021
Q3 		$123K Buy
+8,267
New +$132K ﹤0.01% 843
2020
Q3 		– Sell
-1,000
Closed -$48K – 1110
2020
Q2 		$48K Buy
+1,000
New +$77.3K ﹤0.01% 564

Other funds holding ICPT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SG3 Management's ICPT Position: Q4 2021 in Review

SG3 Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2021, closing a stake of 8,267 shares — an estimated $139K sold.

SG3 Management first reported a position in ICPT in Q2 2020 and held it in 2 quarters. The position peaked at $123K in Q3 2021. 147 funds tracked by Wall St. Rank hold ICPT as of Q4 2021.

  • SG3 Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 8,267 Intercept Pharmaceuticals, Inc. shares in Q4 2021, an estimated $139K.
  • SG3 Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2020 and held it in 2 quarters.
  • SG3 Management's Intercept Pharmaceuticals, Inc. position peaked at $123K in Q3 2021.
  • 147 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.